Ardelyx Stock News

Ardelyx, Inc. (ARDX) with the stream of 2.41% also noticed, India Timber Pharmaceuticals, Inc. (TMBR) encountered a rapid change of 6.14% in the last hour of Wednesday’s trading session. Ardelyx, … The post Have an attention on: Ardelyx, Inc. (NASDAQ:ARDX), Timber Pharmaceuticals, Inc. (AMEX:TMBR) appeared first on Stocks Equity .

Brokerages forecast that Ardelyx, Inc. (NASDAQ:ARDX) will report $1.00 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Ardelyxs earnings, with the highest sales estimate coming in at $2.00 million and the lowest estimate coming in at $0.00. Ardelyx reported sales of $1.81 million during the same quarter []

Analysts forecast that Ardelyx, Inc. (NASDAQ:ARDX) will post $1.00 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Ardelyxs earnings, with the highest sales estimate coming in at $2.00 million and the lowest estimate coming in at $0.00. Ardelyx posted sales of $1.81 million during the same []

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Ardelyx, Inc. (NASDAQ:ARDX) was the recipient of a large growth in short interest in the month of October. As of October 29th, there was short interest totalling 7,690,000 shares, a growth of 18.5% from the October 14th total of 6,490,000 shares. Currently, 9.3% of the companys stock are sold short. Based on an average daily []

Goldman Sachs Group Inc. decreased its position in Ardelyx, Inc. (NASDAQ:ARDX) by 13.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 420,422 shares of the biopharmaceutical companys stock after selling 65,863 shares during the quarter. Goldman Sachs Group Inc.s holdings []

Ardelyx, Inc. (NASDAQ:ARDX) has been assigned an average recommendation of Hold from the nine research firms that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have []

Ardelyx Inc. (NASDAQ:ARDX) price on Thursday, November 18, fall -3.15% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.99. A look at the stocks price movement, the close in the last trading session was $1.02, moving within a range at $0.9827 and $1.06. The beta value (5-Year Ardelyx Inc. (NASDAQ: ARDX): Overvalued Against Others? Read More »

Ardelyx Inc. (NASDAQ:ARDX)s traded shares stood at 2.1 million during the last session, with the companys beta value hitting 1.71. At the close of trading, the stocks price was $1.02, to imply a decrease of -2.86% or -$0.03 in intraday trading. The ARDX shares 52-week high remains $9.23, putting it -804.9% down since that peak Boom Or Bust: What Are Ardelyx Inc.s (NASDAQ:ARDX) Future Prospects? Read More »

Ardelyx, Inc. (NASDAQ:ARDX) – Jefferies Financial Group lowered their FY2021 earnings per share (EPS) estimates for Ardelyx in a research report issued on Monday, November 15th. Jefferies Financial Group analyst C. Howerton now expects that the biopharmaceutical company will post earnings per share of ($1.50) for the year, down from their prior forecast of ($1.49). […]

Ardelyx (NASDAQ:ARDX) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.07), MarketWatch Earnings reports. Ardelyx had a negative return on equity of 99.11% and a negative net margin of 1,009.33%. Shares of ARDX stock traded down $0.04 []

Ardelyx (ARDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ardelyx did not get much clarity from the Type A meeting. Tenapanor's future remains unclear.

The stock price of Ardelyx Inc (NASDAQ: ARDX) fell by over 17% today. This is why it happened.